2025 Sponsors

From advanced wound care through surgery and sports medicine, we are committed to empowering healing by confidently and reliably delivering clinicians the range of regenerative tissue innovations along with the services they need.

Designed for the management of chronic and acute wounds, our portfolio of advanced wound care solutions can support patients from early in the wound healing process through to wound closure—regardless of wound type.

At Extremity Care we offer a diverse portfolio of cell and tissue products - including placental allografts, xenografts, acellular dermis, and conservative wound care products.

We focus on technologies that support the repair, reconstruction, replacement, or supplementation of the patient’s own tissue. Through our dedicated lab and AATB accredited tissue bank we are at the forefront of cell and tissue engineering. We strive to be good stewards of the precious gift of tissue donation.

With our careLOG™ shipping logistics process, we provide just-in-time handling of cell and tissue products. careLOG™ contains the tissue, product information and the billing-related documents needed to request reimbursement.

Surgeons and scientists founded Imbed Biosciences to create breakthrough wound care technologies to positively impact the lives of patients with acute, chronic and traumatic wounds. Imbed is committed to bringing the most advanced wound care solutions to clinics and hospitals nationwide.

.

Sponsor bio coming soon!

In the meantime, check out their website HERE

Convatec has the first and only FDA-cleared placental medical devices for chronic wounds, surgical wounds, and burns with its innovative InnovaMatrix® technology platform -- now available in powder form and a variety of membrane sizes. For more information, visit www.innovamatrix.com.

Sponsor bio coming soon!

In the meantime, check our their website HERE

.

Kerecis is pioneering the use of fish skin and fatty acids in the globally expanding cellular-therapy and regenerative-medicine markets. The fatty-acid-rich products from the company’s patented technologies protect the body’s own tissues and enable the body to regenerate tissues. Developed and manufactured in Isafjordur, Iceland, Kerecis medical products are authorized for sale in Europe, the United States. and several other jurisdictions for human-tissue repair. Thousands of patients are treated annually with our technology. And we are broadening our product line to address many more types of soft-tissue damage.

.

At 180 Health Services, we are committed to being your trusted partner in advanced medical solutions. Our mission is to deliver cutting edge, life-enhancing wound care products to providers throughout the country. We take pride in our extensive range of innovative skin graft biologics for the treatment of non-healing wounds.

Headquartered in Auckland, New Zealand, Aroa Biosurgery is a global medical device company committed to unlocking regenerative healing for everybody through its patented AROA ECM™ complex wound and tissue reconstruction products.

The company was founded in 2008 by Veterinarian Surgeon Dr Brian Ward, who discovered that a tissue scaffold called the extra cellular matrix (ECM) found in the forestomach of sheep has a similar structure to human tissue and contains over 150 proteins known to be important in the healing process.

Aroa Biosurgery has established USA operations, regulatory approval in over 50 countries and employs over 270 people across New Zealand and North America. To date, more than 6 million AROA ECM™ devices have been used in treating patients worldwide.

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA-registered and AATB-accredited site in Pompano Beach, Florida.

ETS, headquartered in Rolla, Missouri, USA, specializes in developing medical products utilizing proprietary borate-based bioactive glass. Our flagship product, Mirragen®, represents a breakthrough in wound care technology as the first FDA-cleared inorganic bioactive glass-based solution. Mirragen® is a borate-based bioactive glass fiber matrix that facilitates quality tissue formation, without the risk of infection that tissue-based products have, all in an easy to use, versatile form factor.

GR Consulting, LLC is a small boutique consulting and advisory firm that specializes in the wound care and surgical wound care markets. GRc focuses on start-up and early-stage companies who need additional bandwidth to support their expanding business. We are a small team of senior leaders who provide support in strategy, geographic expansion, market access/reimbursement, health economics & outcomes research, regulatory, clinical trial design/execution, and strategic partner searches. Our team has more than 125 years of combined senior level experience and provides the leadership firepower, technical ingenuity, a strong industry network and the expertise to help execute the correct business strategy at the right time. Finally, our business model is set-up to deliver a customized approach to each client’s specific business needs without the bloated overhead and generalist approach that most mid-sized or large consulting firms provide.

The MIMOSA Pro consists of a pocket-sized imaging device and a HIPAA-compliant web portal that streamlines tissue health assessments by capturing temperature, tissue oxygenation, and digital images in less than one second. The images automatically upload to the web portal where clinicians can monitor patient progress and collaborate towards improved outcomes.

RedDress is dedicated to developing revolutionary, biologic advanced wound care solutions based on its patented whole blood technology to recreate the body’s natural healing processes. ActiGraftPRO from RedDress is an innovative autologous point-of-care wound management solution that harnesses your patient's own blood. Once applied, the whole blood clot serves as a protective covering and optimizes the body's own healing potential.

For more information, visit www.reddressmedical.com.

Reprise Biomedical is focused on the development and commercialization of biological medical devices that offer advanced solutions for wound healing. In 2019, Reprise took ownership of two products, under a proprietary perfusion decellularization technology license from the University of Minnesota, MiroDerm biologic wound matrix for advanced wound management and MiroFlex biologic matrix for soft tissue reinforcement. Reprise is committed to delivering novel solutions which address unmet surgical needs for advanced wound care. Our transformational, Miro3D wound matrix, is an example of that commitment. Miro3D broadens our wound management portfolio by offering a unique three-dimensional solution for deep and tunnelling wounds.

Royal Wound-X is a pioneering leader in wound care research and development, committed to delivering top-tier, innovative biologic solutions that enhance the healing process and improve patients' quality of life. Recognized for its focus on advanced wound care, Royal Wound-X places patient well-being at the center of its mission, offering an exceptional standard of care to address a variety of complex wound and tissue repair needs. At Royal Wound-X, our mission is driven by patient-centered care, innovation and excellence, and integrity and compassion. Royal Wound-X provides a comprehensive array of products tailored to meet the varied needs of the wound care industry, including amniotic, dermal, collagen, synthetic, and platelet-rich fibrin matrix (PRFM) products. As a rapidly expanding force in the industry, Royal Wound-X is continuously developing and launching new products and solutions that set benchmarks for quality, effectiveness, and patient outcomes. Royal Wound-X’s commitment to research and innovation keeps it at the forefront of wound care, helping shape the future of healthcare and improving lives globally.

Samaritan Biologics is a Tennessee based, minority owned small business located in Memphis with R&D and future manufacturing facilities based in Greenville South Carolina on the campus of Clemson University. Samaritan was bootstrapped by 3 founders in 2019 and has no outside investment or physician ownership. Our focus is the development and commercialization of human perinatal tissue allografts to enable doctors to more effectively treat patients for a wide variety of clinical goals including: Limb Preservation, Wound Care, Robotic Oncology, Neurosurgery, Urology, Sports Medicine and Orthopedics. We pride ourselves on taking a scientific approach to perinatal tissues. We live our tagline everyday – Helping, Healing, Giving

Stability Biologics is an innovative, regenerative medicine company, providing a full line of advanced biologic products to enhance the lives of patients and create greater surgeon satisfaction. ​